Precancer atlas to drive precision prevention trials

Avrum Spira, Matthew B. Yurgelun, Ludmil Alexandrov, Anjana Rao, Rafael Bejar, Kornelia Polyak, Marios Giannakis, Ali Shilatifard, Olivera J. Finn, Madhav Dhodapkar, Neil Elliot Kay, Esteban D Braggio, Eduardo Vilar, Sarah A. Mazzilli, Timothy R. Rebbeck, Judy E. Garber, Victor E. Velculescu, Mary L. Disis, Douglas C. Wallace, Scott M. Lippman

Research output: Contribution to journalReview article

46 Scopus citations

Abstract

Cancer development is a complex process driven by inherited and acquired molecular and cellular alterations. Prevention is the holy grail of cancer elimination, but making this a reality will take a fundamental rethinking and deep understanding of premalignant biology. In this Perspective, we propose a national concerted effort to create a Precancer Atlas (PCA), integrating multi-omics and immunity - basic tenets of the neoplastic process. The biology of neoplasia caused by germline mutations has led to paradigm-changing precision prevention efforts, including: tumor testing for mismatch repair (MMR) deficiency in Lynch syndrome establishing a new paradigm, combinatorial chemoprevention efficacy in familial adenomatous polyposis (FAP), signal of benefit from imaging-based early detection research in high-germline risk for pancreatic neoplasia, elucidating early ontogeny in BRCA1-mutation carriers leading to an international breast cancer prevention trial, and insights into the intricate germlinesomatic- immunity interaction landscape. Emerging genetic and pharmacologic (metformin) disruption of mitochondrial (mt) respiration increased autophagy to prevent cancer in a Li-Fraumeni mouse model (biology reproduced in clinical pilot) and revealed profound influences of subtle changes in mt DNA background variation on obesity, aging, and cancer risk. The elaborate communication between the immune system and neoplasia includes an increasingly complex cellular microenvironment and dynamic interactions between host genetics, environmental factors, and microbes in shaping the immune response. Cancer vaccines are in early murine and clinical precancer studies, building on the recent successes of immunotherapy and HPV vaccine immune prevention. Molecular monitoring in Barrett's esophagus to avoid overdiagnosis/treatment highlights an important PCAtheme. Next generation sequencing (NGS) discovered age-related clonal hematopoiesis of indeterminate potential (CHIP). Ultra-deep NGS reports over the past year have redefined the premalignant landscape remarkably identifying tiny clones in the blood of up to 95% of women in their 50s, suggesting that potentially premalignant clones are ubiquitous. Similar data from eyelid skin and peritoneal and uterine lavage fluid provide unprecedented opportunities to dissect the earliest phases of stem/progenitor clonal (and microenvironment) evolution/diversity with new singlecell and liquid biopsy technologies. Cancer mutational signatures reflect exogenous or endogenous processes imprinted over time in precursors. Accelerating the prevention of cancer will require a largescale, longitudinal effort, leveraging diverse disciplines (from genetics, biochemistry, and immunology to mathematics, computational biology, and engineering), initiatives, technologies, and models in developing an integrated multi-omics and immunity PCA - an immense national resource to interrogate, target, and intercept events that drive oncogenesis.

Original languageEnglish (US)
Pages (from-to)1510-1541
Number of pages32
JournalCancer Research
Volume77
Issue number7
DOIs
StatePublished - 2017

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Spira, A., Yurgelun, M. B., Alexandrov, L., Rao, A., Bejar, R., Polyak, K., Giannakis, M., Shilatifard, A., Finn, O. J., Dhodapkar, M., Kay, N. E., Braggio, E. D., Vilar, E., Mazzilli, S. A., Rebbeck, T. R., Garber, J. E., Velculescu, V. E., Disis, M. L., Wallace, D. C., & Lippman, S. M. (2017). Precancer atlas to drive precision prevention trials. Cancer Research, 77(7), 1510-1541. https://doi.org/10.1158/0008-5472.CAN-16-2346